Johnson & Johnson ($JNJ) Stock Forecast: Down 0.6% Today

What is Johnson & Johnson?

Johnson & Johnson (JNJ) is a multinational corporation known for its healthcare products, including pharmaceuticals, medical devices, and consumer goods. The stock is listed on the New York Stock Exchange (NYSE).

Why is Johnson & Johnson going down?

JNJ stock is down 0.6% on Aug 22, 2025 14:43

• J&J's bearish movement today could be attributed to the potential drug import tariffs proposed by the government, leading to uncertainty and negative sentiment among investors.
• The sale of J&J stock by Representative Thomas Kean might have also contributed to the downward pressure on the stock, as large sell-offs by insiders can sometimes signal lack of confidence in the company's future performance.
• Despite recent developments, J&J's commitment to investing $2 billion in its U.S. manufacturing operations could be seen as a positive long-term move, potentially enhancing its production capabilities and competitiveness in the market. However, the immediate market reaction seems to be influenced more by the tariff threats and insider selling.

JNJ Price Chart

JNJ Technical Analysis

JNJ News

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs - AstraZeneca ( NASDAQ:AZN ) , Biogen ( NASDAQ:BIIB )

Johnson & Johnson JNJ is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration. J&J announced its investment on Thursday, as reported by Reuters.

https://www.benzinga.com/news/health-care/25/08/47276660/jj-commits-2-billion-to-us-manufacturing-expansion-amid-threat-of-drug-tariffs

Congressional Trading Report: Rep. Thomas Kean Sold Over $31K In Johnson & Johnson Stock - Check Point Software ( NASDAQ:CHKP ) , Johnson & Johnson ( NYSE:JNJ )

August 20, 2025 records indicate that Representative Thomas Kean filed a sale of Johnson & Johnson JNJ, valued between $31,003 and $115,000. According to the August filing, the transaction occurred on July 31, 2025. Currently, Johnson & Johnson shares are trading up 0.16% at $179.13.

https://www.benzinga.com/insights/government/25/08/47261595/congressional-trading-report-rep-thomas-kean-sold-over-31k-in-johnson-johnson-stock

Trending Today

Johnson & Johnson Price History

01.03.2025 - JNJ Stock was down 5.3%

• The bearish movement in JNJ stock could be attributed to the announcement from Nanobiotix regarding the first data from a Phase 1 study evaluating NBTXR3 as a therapy for patients with locally advanced NSCLC. This news might have caused some investors to shift their focus towards the potential of this new therapy, leading to a temporary sell-off of JNJ shares.
• The discussion around finding high-growth dividend stocks could have also influenced investor sentiment, with some possibly reallocating their investments based on the perceived growth potential of other dividend stocks.
• Overall, the market movement in JNJ today seems to be driven by a combination of factors related to potential competition in the healthcare sector and the search for high-growth opportunities in dividend stocks.

07.00.2025 - JNJ Stock was up 2.5%

• JNJ stock closed at $144.62 with a +0.89% change from the previous close.
• Smart money is seen to bet big on JNJ options, reflecting a positive outlook on the stock.
• Speculation on JNJ surpassing earnings expectations is contributing to the bullish trend.
• Investors are viewing JNJ favorably amidst market downturns, indicating it as a stable investment in the current economic climate.

07.00.2025 - JNJ Stock was up 2.0%

• The strong bullish movement in JNJ is believed to be influenced by smart money activities in JNJ options, reflecting a positive sentiment from wealthy investors.
• The bearish strategy utilized by these investors might have bolstered confidence in the stock, resulting in a rise in its value.
• The notable surge in JNJ options points towards a general optimism among market participants regarding the company's future prospects, thereby contributing to today's bullish trend in the stock.

15.09.2024 - JNJ Stock was up 2.8%

• Johnson & Johnson reported impressive Q3 earnings with both revenue and EPS beating expectations, driven by strong sales of cancer drugs.
• The revision of annual outlook to reflect the V-Wave acquisition also contributed to the positive sentiment surrounding the stock.
• Analysts revising their forecasts ahead of the earnings call and high-rolling investors positioning themselves bullish on JNJ further added to the optimism in the market.
• The overall positive earnings report and strategic acquisitions seem to have fueled investor confidence, leading to the bullish movement in Johnson & Johnson's stock price today.

06.08.2023 - JNJ Stock was down 2.3%

• The bearish movement of JNJ stock today can be attributed to the following factors:
• 1. Market sentiment: The overall market sentiment might be bearish, leading to a decline in JNJ stock along with other stocks.
• 2. Cidara Therapeutics announcement: The news about Cidara Therapeutics announcing Janssen's election to proceed under its license agreement relating to novel drug-Fc conjugates targeting influenza may have impacted JNJ stock negatively. This announcement could indicate potential competition in the influenza treatment market, affecting investor confidence in JNJ's pharmaceutical division.
• 3. Idorsia deal with Janssen Biotech: The news of Idorsia reaching a deal with Janssen Biotech, affiliated with Johnson & Johnson, for the return of rights for Aprocitentan might have caused some uncertainty among investors. This deal could have implications for JNJ's future drug development pipeline and potentially affect its revenue prospects.
• 4. Arm's IPO ambitions: The news of Arm halving its IPO ambitions to $4.87 billion, surpassing the listing of Johnson & Johnson consumer health spinoff Kenvue, could have indirectly impacted JNJ stock. This news might have shifted investor attention away from JNJ, leading to a decline in its stock price.
• Overall, the bearish movement of JNJ stock today could be influenced by a combination of market sentiment, competition in the influenza treatment market, uncertainty surrounding future drug development, and the diversion of investor attention to other IPOs.

20.06.2023 - JNJ Stock was up 4.4%

• The bullish movement in JNJ stock today can be attributed to the following factors:
• 1. Strong Q2 Earnings: Johnson & Johnson reported better-than-expected Q2 earnings, with adjusted earnings per share of $2.80, beating the consensus of $2.62. Sales also increased by 6.3% to $25.5 billion, surpassing the consensus of $24.63 billion. This positive financial performance likely contributed to the bullish market movement.
• 2. Positive Jobs Data: The Australian job market showed better-than-expected results, with an addition of 32.6K jobs, surpassing the expected 15.4K. This positive employment data may have had a spillover effect on JNJ stock, as it indicates a strong economy and potential increased demand for healthcare products.
• 3. Overall Market Sentiment: The broader market sentiment, with the Dow industrial average rising for the 8th consecutive day and the S&P index and Dow industrial average having risen 7 of the last 8 trading days, may have also influenced the bullish movement in JNJ stock.
• 4. DARZALEX Sales: Genmab reported strong worldwide net trade sales of DARZALEX, a product co-developed with Johnson & Johnson. This positive sales report may have indirectly impacted the market sentiment towards JNJ stock.
• Overall, the combination of strong earnings, positive jobs data, favorable market sentiment, and positive sales reports contributed to the bullish movement in JNJ stock today.

16.06.2025 - JNJ Stock was up 5.9%

• JNJ raised its FY2025 earnings guidance, leading to a surge in its stock price.
• The company's Q2 earnings beat estimates, with an increase in revenue, which further boosted investor confidence.
• With the broader market showing signs of rebound, investors are turning to defensive positions like medical stocks, including JNJ, ahead of their Q2 reports.
• The focus on AI-driven medical device stocks, including JNJ, indicates a growing interest in innovative healthcare technologies, potentially contributing to the positive market sentiment around the company.

16.06.2025 - JNJ Stock was up 5.4%

• JNJ stock experienced a strong bullish movement today.
• The bullish trend can be attributed to JNJ's Q2 earnings report exceeding expectations, with an EPS of $2.77 and a revenue increase of 5.8% to $23.74 billion.
• The raised 2025 adjusted EPS forecast and sales outlook further boosted investor confidence in the company's performance.
• Analysts and investors may have been impressed by JNJ's strategic positioning in the healthcare sector, especially considering the defensive nature of medical stocks in uncertain market conditions.

17.06.2024 - JNJ Stock was up 4.1%

• JNJ stock showed strong bullish momentum even as the company adjusted its guidance downwards.
• The positive market response could be linked to Johnson & Johnson surpassing earnings expectations, although the stock price dropped due to revised guidance.
• Investor attention may be directed towards JNJ's consistent growth and diverse business model, factors that have historically contributed to the company's ability to navigate different market environments successfully.
• Despite concerns about the revised guidance, JNJ's history of steady earnings growth and sustainable dividend yield may be providing reassurance to investors and fueling the upward trend in the stock.

10.06.2025 - JNJ Stock was up 1.9%

• JNJ stock showed a positive movement today, possibly reflecting optimistic market sentiment and investor confidence.
• Speculations of surpassing earnings predictions have influenced the upward trend, suggesting robust financial performance and growth opportunities for the company.
• The disclosure of regulatory alignment and a recent patent application for JNJ-1900 by Nanobiotix could have also uplifted investor confidence, hinting at potential progress in cancer treatment.
• Backed by a track record of exceeding earnings expectations and favorable market conditions, JNJ continues to attract investors interested in promising returns within the healthcare sector.

22.07.2025 - JNJ Stock was down 0.6%

• J&J's bearish movement today could be attributed to the potential drug import tariffs proposed by the government, leading to uncertainty and negative sentiment among investors.
• The sale of J&J stock by Representative Thomas Kean might have also contributed to the downward pressure on the stock, as large sell-offs by insiders can sometimes signal lack of confidence in the company's future performance.
• Despite recent developments, J&J's commitment to investing $2 billion in its U.S. manufacturing operations could be seen as a positive long-term move, potentially enhancing its production capabilities and competitiveness in the market. However, the immediate market reaction seems to be influenced more by the tariff threats and insider selling.

01.03.2025 - JNJ Stock was down 5.4%

• The downward trend in JNJ's stock price today is associated with the repeated dismissal of using bankruptcy to resolve talc cancer claims. This legal setback suggests potential financial risks and uncertainties for the company.
• JNJ's choice to contest talc lawsuits instead of settling has reversed $7 billion in legal reserves, indicating a shift in their legal approach that investors may perceive as risky.
• The recent disclosure of positive data from a clinical trial by Nanobiotix is unrelated to JNJ's talc lawsuits and is unlikely to have impacted the bearish movement in JNJ's stock today.
• Concerns about the lasting effects of the ongoing talc litigations on JNJ's finances and reputation may be influencing investors, contributing to the bearish market activity.